Provided by Tiger Fintech (Singapore) Pte. Ltd.

Eli Lilly

869.58
-43.1800-4.73%
Post-market: 867.75-1.8300-0.21%19:59 EST
Volume:4.82M
Turnover:4.22B
Market Cap:824.51B
PE:74.26
High:908.00
Open:905.39
Low:861.39
Close:912.76
Loading ...

Hims & Hers Stumbles as GLP-1 Compounding Ends. Lilly Presses the Advantage. -- Barrons.com

Dow Jones
·
25 Feb

Eli Lilly Shares up 2.8% After Co Launches Higher Dose Vials of Weight-Loss Drug for $150 Less Than Injector Pen

THOMSON REUTERS
·
25 Feb

BRIEF-Organovo’S FXR Program, Including FXR314, To Be Acquired By Eli Lilly And Company

Reuters
·
25 Feb

BUZZ-U.S. STOCKS ON THE MOVE-  Eli Lilly, Krispy Kreme, PayPal

Reuters
·
25 Feb

Eli Lilly trims price of weight-loss drug Zepbound for out-of-pocket payers

Dow Jones
·
25 Feb

BUZZ-Organovo rises as Eli Lilly acquires co's FXR program

Reuters
·
25 Feb

Eli Lilly and Company (LLY): A High Growth Mega Cap Stock You Can Buy and Hold for the Next 5 Years

Insider Monkey
·
25 Feb

Organovo Holdings Shares More Than Triple Premarket After Eli Lilly to Buy Co's Liver and Bowel Disease Drug Program

THOMSON REUTERS
·
25 Feb

Organovo’s FXR program to be acquired by Eli Lilly

TIPRANKS
·
25 Feb

Organovo Holdings Inc - to Receive Upfront Payment and Milestones for Fxr314

THOMSON REUTERS
·
25 Feb

Organovo’s Fxr Program, Including Fxr314, to Be Acquired by Eli Lilly and Company

THOMSON REUTERS
·
25 Feb

Organovo Holdings Inc - Lilly Acquires All Commercial and Ip Rights to Fxr Program

THOMSON REUTERS
·
25 Feb

Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company

GlobeNewswire
·
25 Feb

Corcept (CORT) Q4 Earnings Report Preview: What To Look For

StockStory
·
25 Feb

Eli Lilly Cuts Price Of Weight-Loss Drug Zepbound For Self-Paying Patients

Dow Jones
·
25 Feb

Eli Lilly Unveils Higher Single-Dose Zepbound Vials for $499 a Month -- Barrons.com

Dow Jones
·
25 Feb